Crohn's Disease Clinical Research Trials

Birmingham : University of Alabama at Birmingham

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Birmingham : University of Alabama at Birmingham

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Birmingham : Apex Clinical Trials

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Birmingham : University of Alabama at Birmingham

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Birmingham : Apex Clinical Trials

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Birmingham : University of Alabama at Birmingham

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Mobile : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Phoenix : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Scottsdale : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tucson : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Jonesboro : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Little Rock : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Los Angeles : Gastrointestinal Bioscience

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Los Angeles : Gastrointestinal Bioscience

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Montebello : Paramount Medical Specialty

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Montebello : Paramount Medical Specialty

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Sacramento : Capital Gastroenterology Consultants Medical Group

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Sacramento : Capital Gastroenterology Consultants Medical Group

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Diego : Clinical Applications Laboratories Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Diego : Desta Digestive Disease Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Diego : Desta Digestive Disease Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Diego : Clinical Applications Laboratories Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Anaheim : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Anaheim : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Francisco : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Glendale : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

La Jolla : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

La Jolla : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

La Jolla : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Los Angeles : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Oakland : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Orange :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Orange : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Orange : Pfizer Investigational Site

This is a Safety Study to Monitor Longer-term Treatment With PF-00547659.

Redlands : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Sacramento : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

San Carlos : Digestive Care Associates, LLC

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

San Diego :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

San Diego : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

San Diego : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

San Diego : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

San Francisco : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

San Francisco : University of California, San Francisco

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

San Francisco : University of California, San Francisco

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

San Francisco : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Stanford :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Whittier : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Aurora : University of Colorado Health Sciences Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Aurora : University of Colorado Health Sciences Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Golden : Rocky Mountain Clinical Research, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Golden : Rocky Mountain Clinical Research, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lafayette : Gastroenterology of the Rockies

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lafayette : Gastroenterology of the Rockies

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Littleton : Arapahoe Gastroenterology Associates P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Littleton : Arapahoe Gastroenterology Associates P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lone Tree : South Denver Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lone Tree : South Denver Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pueblo : Lynn Institute of Pueblo

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pueblo : Lynn Institute of Pueblo

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Denver : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Denver : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Denver : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Lafayette : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Lakewood : Rocky Mountain Gastroenterology Associates

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Lakewood : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Lakewood : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lakewood : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Littleton :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Littleton : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Littleton : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Littleton : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Littleton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Thornton : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Thornton : Pfizer Investigational Site

This is a Safety Study to Monitor Longer-term Treatment With PF-00547659.

Bristol : Connecticut Gastroenterology Institute

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Bristol : Connecticut Gastroenterology Institute

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Hamden : Gastroenterology Center of Connecticut, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Hamden : Gastroenterology Center of Connecticut, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Bridgeport : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Bridgeport : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Glastonbury :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Hamden : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Hamden : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hartford : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Middletown :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

New Haven :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

New Haven : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Clearwater : Clinical Research of West Florida, Inc.

Are you interested in taking part in a New Research Study of an Investigational drug for CROHN'S DISEASE?

Clearwater : Clinical Research of West Florida, Inc.

Crohn's disease research study

Gainesville : University of Florida

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Gainesville : University of Florida

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Jacksonville : University of Florida, Jacksonville

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Jacksonville : Borland-Groover Clinic

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Jacksonville : East Coast Institute for Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Jacksonville : Borland-Groover Clinic

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Jacksonville : East Coast Institute for Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Jacksonville : University of Florida, Jacksonville

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Maitland : Center for Advanced Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Maitland : Center for Advanced Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Melbourne : Osler Clinical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Melbourne : Osler Clinical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Miami : University of Miami Miller School of Medicine

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Miami : University of Miami Miller School of Medicine

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New Smyrna Beach : United Medical Research Institute

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New Smyrna Beach : United Medical Research Institute

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Orlando : Internal Medicine Specialists

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Orlando : Compass Research LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Orlando : Internal Medicine Specialists

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Orlando : Compass Research LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Tampa : West Wind'r Research & Development, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tampa : University of South Florida

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tampa : University of South Florida

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Tampa : West Wind'r Research & Development, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Clearwater : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Clearwater : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Clearwater : Clinical Research of West Florida

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Clearwater : Clinical Research of West Florida

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Crystal River : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Gainesville :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Gainesville : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Inverness : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Jacksonville :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Largo : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Miami :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Miami : Jackson Memorial Hospital

Prevalence of Cytomegalovirus, Epstein Barr Virus and Human Herpes 6 Virus in Inflammatory Bowel Disease

Miami : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Naples :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Naples : Gastroenterology Group of Naples

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Naples : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

New Port Richey : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Orlando : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Orlando : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Orlando : Pfizer Investigational Site

This is a Safety Study to Monitor Longer-term Treatment With PF-00547659.

Port Orange : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Sanford : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Sanford : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Tampa : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Trinity : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Weston :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Winter Park :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Winter Park : Shafran Gastroenterology Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Winter Park :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Winter Park : Shafran Gastroenterology Center

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

Winter Park : Shafran Gastroenterology Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Winter Park : Shafran Gastroenterology Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Zephyrhills : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Atlanta : Atlanta Gastroenterology Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Atlanta : Atlanta Gastroenterology Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Decatur : Atlanta Center for Gastroenterology, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Decatur : Atlanta Center for Gastroenterology, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Macon : Gastroenterology Associates of Central Georgia

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Macon : Gastroenterology Associates of Central Georgia

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Newnan : Digestive Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Newnan : Digestive Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Savannah : St. Joseph's/Candler Health System

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Savannah : St. Joseph's/Candler Health System

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Snellville : DLW Research System

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Snellville : DLW Research System

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Atlanta : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Atlanta : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Atlanta : Atlanta Gastroenterology Associates

Optimizing Cimzia in Crohn's Patients

Atlanta : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Decatur :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Decatur : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Decatur : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Macon :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Macon : Gastroenterology Associates of Central Georgia

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Macon :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Macon : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Marietta : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Marietta : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Boise : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Chicago : Rush University Medical Center - Treatment Research Center

Dysbiosis in inflammatory bowel disease.

Chicago : Rush University Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chicago : University of Chicago Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chicago : University of Chicago Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chicago : Rush University Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Urbana : Carle Clinic Association P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Urbana : Carle Clinic Association P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chicago :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Chicago : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chicago : University of Chicago Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Chicago : University of Chicago

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chicago : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Indianapolis : Indianapolis Gastroenterology & Hepatology, Inc.- ARC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Indianapolis : Indianapolis Gastroenterology & Hepatology, Inc.- ARC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

4602 :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Anderson : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Indianapolis : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Indianapolis : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Clive : Iowa Digestive Disease Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Clive : Digestive & Liver Consultants

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Clive : Iowa Digestive Disease Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Clive : Digestive & Liver Consultants

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Clive :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Clive :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Clive : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Iowa City :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Kansas City : University Of Kansas

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Kansas City : University Of Kansas

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Topeka : Cotton O'Neil Digestive Health Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Topeka : Cotton O'Neil Digestive Health Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pratt :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Topeka : Cotton-O'Neil Clinical Research Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Topeka : Cotton-O'Neil Clinical Research Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Lexington : University of Kentucky Chandler Medical Center

Does your Crohn's require surgery?

Lexington : University of Kentucky Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lexington : University of Kentucky Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Louisville : University Of Louisville

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Louisville : University Of Louisville

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Louisville : University Of Louisville

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lexington :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Lexington : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Baton Rouge : Gastroenterology Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Baton Rouge : Gastroenterology Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Baton Rouge :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Baton Rouge :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hammond : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hammond : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Monroe : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Monroe : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Monroe : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

New Orleans :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

New Orleans : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Portland : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Chevy Chase : Metropolitan Gastroenterology Group, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research

Ulcerative Colitis and Crohn’s Disease (IBD) Research Study

Prince Frederick : Shah Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Prince Frederick : Shah Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Annapolis : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Annapolis : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Baltimore :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Baltimore : University of Maryland, Baltimore

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Baltimore : University of Maryland, Baltimore

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Baltimore : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Bethesda :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Chevy Chase :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Chevy Chase : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chevy Chase : Chevy Chase Clinical Research

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Chevy Chase : Chevy Chase Clinical Research

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Chevy Chase : Metropolitan Gastroenterology Group, Pc, Chevy Chase Cr Updated

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Chevy Chase : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chevy Chase : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Chevy Chase : Pfizer Investigational Site

This is a Safety Study to Monitor Longer-term Treatment With PF-00547659.

Hollywood : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Towson :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Towson : Endoscopic Microsurgery Associates PA

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Towson :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Boston : Massachusetts General Hospital

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Boston : Boston Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Boston : Massachusetts General Hospital

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Boston : Boston Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Boston : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Boston : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Fall River : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Worcester : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Dearborn : The Center for Clinical Studies

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Dearborn : The Center for Clinical Studies

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Troy : Center for Digestive Health

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Troy : Center for Digestive Health

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Wyoming : Gastroenterology Associates of Western Michigan, P.L.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Wyoming : Gastroenterology Associates of Western Michigan, P.L.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Ann Arbor :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Ann Arbor : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ann Arbor : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chesterfield :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Chesterfield : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Chesterfield : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chesterfield : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Detroit : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Troy :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Troy : Center for Digestive Health

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Troy : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Utica : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Plymouth : Minnesota Gastroenterology, P.A.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Plymouth : Minnesota Gastroenterology, P.A.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Rochester : Mayo Clinic

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Rochester : Mayo Clinic

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Minneapolis : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Plymouth :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Plymouth : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Rochester :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Rochester : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Rochester : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Rochester : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Rochester : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Saint Paul : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Tupelo : Digestive Health Specialists

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tupelo : Digestive Health Specialists

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Jackson : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ocean Springs : Digestive Health Center

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Ocean Springs :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tupelo : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Kansas City : Truman Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Kansas City : Truman Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lees Summit : Midwest Center for Clinical Research

Study of an investigational medication from Bristol Myers Squibb in patients with moderate to severe active Crohn's Disease.

Lees Summit : Midwest Center for Clinical Research

Study of an investigational medication from GlaskoSmithKline to evaluate two oral doses of GSK1605786 (GSK786) as compared to placebo in the induction of clinical response over a 12-week treatment period in subjects with moderately to severely active Crohn’s disease.

Lees Summit : Midwest Center for Clinical Research

Study of Stelara, an investigational medication from Centocor/Johnson&Johnson to evaluate the safety and efficacy of Ustekinumab (Stelara) in patients with moderately to severely active Crohn's Disease.

Mexico : Center for Digestive and Liver Diseases, Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Mexico : Center for Digestive and Liver Diseases, Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

St. Louis : Washington University

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

St. Louis : Washington University

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Columbia : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Kansas City : The Children's Mercy Hospital

Effect of VSL#3 on Intestinal Permeability in Pediatric Crohn's Disease

Lees Summit :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Lees Summit :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Lee'S Summit : Midwest Center For Clinical Research Updated

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Mexico : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

St Louis : St Louis Center for Clinical Studies

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Research

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

St. Louis : Saint Louis Center for Clinical Research

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

St. Louis : St. Louis Center for Clinical Studies

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Boys Town : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Las Vegas : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Lebanon : Dartmouth-Hitchcock Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Lebanon : Dartmouth-Hitchcock Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Lebanon : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lebanon : Dartmouth Hitchcock Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Lebanon : Dartmouth HItchcock Medical Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Morristown : Affiliates in Gastroenterology PA

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Morristown : Affiliates in Gastroenterology PA

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New Brunswick : University of Medicine and Dentistry of New Jersey-NJMS

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New Brunswick : University of Medicine and Dentistry of New Jersey-NJMS

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Vineland : The Gastroenterology Group of South Jersey

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Vineland : The Gastroenterology Group of South Jersey

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Berlin : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Mays Landing : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Morristown : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Morristown : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Bayside : Hepatobiliary Associates of New York

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Bayside : Hepatobiliary Associates of New York

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Cheektowaga : Digestive Health Physician

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Cheektowaga : Digestive Health Physician

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Great Neck : Long Island Clinical Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Great Neck : Long Island Clinical Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Merrick : Long Island Gastroenterology Group, P.C.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Merrick : Long Island Gastroenterology Group, P.C.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New York : Present Chapman Marion Steinlauf MD PC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New York : New York Presbyterian Hospital

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

New York : Present Chapman Marion Steinlauf MD PC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

New York : New York Presbyterian Hospital

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pittsford : Kim, Chung MD (Private Practice)

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pittsford : Kim, Chung MD (Private Practice)

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Poughkeepsie : Gastroenterology Associates

A Non-Interventional Long-term Post-Marketing Registry of Patients Treate with Certolizumab Pegol (Cimzia®) for Crohn's Disease

Rochester : University of Rochester

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Rochester : University of Rochester

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Setauket : Long Island Digestive Disease Consultants

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Setauket : Long Island Digestive Disease Consultants

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Stonybrook : SUNY Stony Brook University Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Stonybrook : SUNY Stony Brook University Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Syracuse : Syracuse Gastroenterological Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Syracuse : Syracuse Gastroenterological Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Brooklyn : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Brooklyn : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Buffalo : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Great Neck :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Great Neck : Long Island Clinical Research Associates, LLP

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Great Neck :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Great Neck : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Great Neck : Long Island Clinical Research Assoc., Llp Updated

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Great Neck : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Great Neck : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Great Neck : Pfizer Investigational Site

This is a Safety Study to Monitor Longer-term Treatment With PF-00547659.

Mineola : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New Hyde Park : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New York :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

New York : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

New York : Mount Sinai School of Medicine

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

New York : Weill Cornell Medical College

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

New York : Mount Sinai School of Medicine

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

New York : Weill Cornell Medical College

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

New York : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

New York : Mount Sinai School of Medicine

Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

Poughkeepsie : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Poughkeepsie : Pfizer Investigational Site

This is a Safety Study to Monitor Longer-term Treatment With PF-00547659.

Stony Brook : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Asheville : Asheville Gastroenterology Associates, P.A.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Asheville : Asheville Gastroenterology Associates, P.A.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Chapel Hill : University of North Carolina at Chapel Hill

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Chapel Hill : University of North Carolina at Chapel Hill

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Charlotte : Charlotte Gastroentology and Hepatology, P.L.L.C

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Charlotte : Charlotte Gastroentology and Hepatology, P.L.L.C

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Elkin : Northwest Piedmont Clinical Research, Inc.

An Open-label Study of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

Elkin : Northwest Piedmont Clinical Research, Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Elkin : Northwest Piedmont Clinical Research, Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Morganton : Burke Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Morganton : Burke Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Raleigh : Wake Research Associates

Crohn’s Disease Research Study

Raleigh : Wake Research Associates

Do you suffer from Crohn’s Disease?

Raleigh : Wake Research Associates

Study of Crohn's Disease Now Enrolling

Raleigh : Wake Research Associates

Treating your Crohn's disease doesn't have to be a solo act.

Winston Salem : Wake Forest University Baptist Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Winston Salem : Wake Forest University Baptist Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Asheville :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Boone : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Chapel Hill :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Chapel Hill : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Chapel Hill : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Chapel Hill : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Charlotte :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Charlotte :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Durham :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Durham : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Durham : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Durham : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Raleigh :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Raleigh :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Raleigh : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Raleigh : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Raleigh : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Beachwood : Gastroenterology Associates of Cleveland, Inc.

Research trial now enrolling for Humira ® for Crohn's Disease

Cincinnati : Consultants for Clinical Research Inc.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Cincinnati : Consultants for Clinical Research Inc.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Cleveland : Cleveland Clinic Foundation

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Cleveland : Cleveland Clinic Foundation

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Dayton : Dayton Science Institute

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Dayton : Dayton Science Institute

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Cincinnati :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Cincinnati : Consultants for Clinical Research

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Cincinnati : Ohio Gastroenterology and Liver

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Cincinnati :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Cincinnati : Consultants For Clinical Research Updated

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Cincinnati : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Cleveland :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Tulsa : Options Health Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tulsa : Options Health Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Oklahoma City :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Oklahoma City : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Oklahoma City : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Oklahoma City : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Oklahoma City, : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tulsa : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tulsa : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Tulsa : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Tulsa : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Tulsa : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Portland : The Oregon Clinic-West Hills Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Portland : The Oregon Clinic-West Hills Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Bend :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Portland :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Portland : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Portland : Oregon Health & Science University

Infliximab, Regulatory T Cells, IL2 and Crohn's Disease

Portland : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Pittsburgh : University of Pittsburgh Medical Center - Cancer Centers

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pittsburgh : University of Pittsburgh Medical Center - Cancer Centers

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Danville : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Duncansville : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

King of Prussia : Omnicare Clinical Research, Inc.

Phase II Study of HMPL-004 in Subjects With Crohn's Disease

Philadelphia : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Pittsburg : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Pittsburg : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Pittsburgh :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Pittsburgh : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Pittsburgh : Children's Hospital of Pittsburgh of UPMC

Autologous Stem Cell Transplantation for Crohn's Disease

Pittsburgh : University of Pittsburgh

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

East Providence : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

East Providence : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Providence : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Providence : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Warwick : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Charleston : Medical University Of SC CAR

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Charleston : Medical University Of SC CAR

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Columbia : Consultants in Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Columbia : Consultants in Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Greenville : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Germantown : Gastroenterology Center of the MidSouth, PC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Germantown : Gastroenterology Center of the MidSouth, PC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Nashville : Vanderbilt University Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Nashville : Vanderbilt University Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Germantown :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Germantown : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Germantown : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Germantown : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Germantown : Gastroenterology Center of the Midsouth

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Germantown : Gastroenterology Center of the Midsouth, PC

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Germantown : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Knoxville : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Memphis : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Nashville :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Nashville : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Nashville : Inflammatory Bowel Disease Clinic c/o Divison of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, Vanderbilt University

Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use

Nashville : Vanderbilt University Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Nashville : Vanderbilt University Medical Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Nashville : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Nashville : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Austin : Austin Gastroenterology, PA

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Austin : Austin Gastroenterology, PA

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Houston : Jacon Medical Research Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Houston : Bayou City Research, Ltd.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Houston : Gastroenterology Consultants

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Houston : Jacon Medical Research Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Houston : Bayou City Research, Ltd.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Houston : Gastroenterology Consultants

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Pasadena : Digestive Health Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Pasadena : Digestive Health Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Antonio : Alamo Medical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Antonio : Stone Oak Research Foundation

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Antonio : Gastroenterology Clinic of San Antonio

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

San Antonio : Alamo Medical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Antonio : Stone Oak Research Foundation

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

San Antonio : Gastroenterology Clinic of San Antonio

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Tyler : Digestive Health Specialists of Tyler

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Tyler : Digestive Health Specialists of Tyler

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Austin : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Austin : Pfizer Investigational Site

B0151003 Open-Label Extension Study

Dallas : Baylor University Medical Center

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Dallas : Baylor University Medical Center

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Dallas : Dallas VA Medical Center

Exacerbating Factors in Inflammatory Bowel Disease

Dallas : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Fort Worth : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Grapevine :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Grapevine : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Grapevine :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Houston : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Pasadena : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Plano :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

San Antonio :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

San Antonio : Gastroenterology Research Of San Antonio Updated

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Sugar Land : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Tyler :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Tyler : Pfizer Investigational Site

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Sandy : Granite Peaks Gastroenterology

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Sandy : Granite Peaks Gastroenterology

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Salt Lake City :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Salt Lake City : University of Utah

A Safety and Efficacy Study of Daikenchuto (TU-100) to Treat Crohn's Disease

Salt Lake City : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Burlington :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Burlington : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Charlottesville : Charlottesville Medical Research

Crohn’s Disease?

Charlottesville : Charlottesville Medical Research

Do you have Crohn’s?

Charlottesville : University of Virginia Health System

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Charlottesville : University of Virginia Health System

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Fairfax : Gastroenterology Associates of Northern Virginia

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Fairfax : Gastroenterology Associates of Northern Virginia

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Norfolk : Digestive and Liver Disease Specialist Ltd.

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Norfolk : Digestive and Liver Disease Specialist Ltd.

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Richmond : Hunter Holmes McGuire VA Medical Center

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Richmond : Hunter Holmes McGuire VA Medical Center

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Virginia Beach : Gastroenterology, Ltd.

A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia®) for Crohn's Disease

Charlottesville :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Charlottesville : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Charlottesville : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Fairfax : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Norfolk : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Richmond : McGuire Research Institute

Evaluation of PROCHYMAL[tm] Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Richmond : McGuire Research Institute

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Bellevue : Northwest Gastroenterology Associates

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Bellevue : Northwest Gastroenterology Associates

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Edmonds : Puget Sound Medical Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Edmonds : Puget Sound Medical Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Seattle :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Seattle : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Seattle : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Seattle : University of Washington Medical Center

Induction of Clinical Response Using Rifaximin in Crohn's Disease

Seattle : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Seattle : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Tacoma :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

200 Pinecrest Plaza, Morgantown : There may be multiple sites in this clinical trial. Please contact United BioSource Corporation

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

Madison : Pharmaseek, LLC

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Madison : Pharmaseek, LLC

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Wisconsin Center for Advanced Research

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Medical College Of Wisconsin

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Wisconsin Center for Advanced Research

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Milwaukee : Medical College Of Wisconsin

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

Madison :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Madison : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Milwaukee : Updated

Study Registry to Evaluate the Long-term Safety of Infliximab and Clinical Status of Pediatric Patients With Inflammatory Bowel Disease

Wauwatosa : Pfizer Investigational Site

Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease That Have Not Responded To Other Treatments.

Adelaide :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Adelaide : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Adelaide : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Adelaide : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Adelaide : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Adelaide : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Bankstown : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bankstown : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Brisbane :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Brisbane : QPharm

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease

Central Queensland M C :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Fitzroy : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Fitzroy : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Fremantle :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Fremantle : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Garran :

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Hersten : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hersten : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Herston :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Kurralta Park : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Melbourne : Center for Clinical Studies

Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn’s Disease

Prahran : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Prahran : Research Site

Multiple Ascending Doses of AMG 139 in Healthy and Crohn's Disease Subjects

Prahran : Research Site

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

Salzburg :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Stolzalpe N/A :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Wien :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Antwerp : UZ Antwerpen

Switching From Adalimumab to Infliximab

Belgium : Belgium

A Study of TRK-170 for the Treatment of Crohn's Disease

Bonheiden :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Bonheiden : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bonheiden : Site Reference ID/Investigator# 38147

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Bonheiden : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Bonheiden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Brussel :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Brussels :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Brussels : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Brussels : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Edegem : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Gent : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ghent : University Hospital Ghent

Switching From Adalimumab to Infliximab

Hasselt : Virga Jesse hospital

Switching From Adalimumab to Infliximab

Kortrijk : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Kortrijk : AZ Groeninge

Switching From Adalimumab to Infliximab

Leuven :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Leuven : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Leuven : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Leuven : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Leuven : UZ Leuven

Switching From Adalimumab to Infliximab

Liege :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Oostende : AZ Damiaan

Switching From Adalimumab to Infliximab

Ottignies : Clinique Saint-Pierre

Switching From Adalimumab to Infliximab

Roeselare :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Roeselare : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Roeselare : Site Reference ID/Investigator# 38146

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Roeselare : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Roeselare : Heilig Hartziekenhuis Roeselare

Switching From Adalimumab to Infliximab

Abbotsford : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Abbotsford : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Brandon :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Calgary :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Calgary : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Calgary : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Calgary : Division of Gastroenterology

Metabolomic Analysis, a Potential Tool to Direct Treatment With Adalimumab in Crohn's Disease (CD)

Edmonton :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Edmonton : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Edmonton : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Guelph :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Halifax :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Halifax : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Halifax : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hamilton : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hamilton : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Kingston :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Kingston : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Levis :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

London :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

London : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

London : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

London : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Montreal :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Montreal : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Montreal : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ottawa : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ottawa : Investigational Site 5

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study)(P05088AM1)

Quebec :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Quebec : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Toronto : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Toronto : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Toronto : Investigational Site 1

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study)(P05088AM1)

Toronto : Investigational Site 4

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study)(P05088AM1)

Vancouver :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Vancouver : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Vancouver : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Vancouver : Investigational Site 3

The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study)(P05088AM1)

Vaughan : Site Reference ID/Investigator# 38155

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Winnipeg :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Winnipeg : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Winnipeg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hradec Kralove : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hradec Kralove : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hradec Kralove : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Olomouc : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Olomouc : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Ostrava - Vitkovice : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ostrava - Vitkovice : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha 10 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Praha 4 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Praha 4 : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Praha 4 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Praha 7 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Aalborg : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Aalborg : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aalborg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Aarhus : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Aarhus : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Aarhus : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Aarhus C : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Herlev : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Herlev : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hvidovre : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hvidovre : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Odense : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Amiens :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Amiens : Site Reference ID/Investigator# 38164

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Amiens cedex 1 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Bordeaux :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Caen :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Clichy cedex : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

France : France

A Study of TRK-170 for the Treatment of Crohn's Disease

Grenoble :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Lille :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Lille cedex : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Lille cedex : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Marseille :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Nice :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Nice : Site Reference ID/Investigator# 42839

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Nice cedex 3 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Paris :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Paris : Hôpital Necker Enfants Malades, Faculté de Médecine Necker, INSERM EMI0212

Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis

Paris cedex 10 : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Paris cedex 10 : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Paris cedex 10 : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Pessac cedex : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Pessac Cedex : Site Reference ID/Investigator# 42818

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Pessac cedex : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Pessac cedex : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Pessac N/A :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Rouen :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Saint-Priest en Jarez : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Vandoeuvre Les Nancy :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Berlin :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Berlin : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Berlin : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Berlin : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Berlin : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Dachau : Site Reference ID/Investigator# 38172

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Erlangen :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Erlangen : Department of Medicine I, University of Erlangen-Nuremberg

Endomicroscopy in IBD Patients

Erlangen : Medizinische Klinik I, University Hospital Erlangen

Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut

Frankfurt am Main : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Frankfurt am Main : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hamburg :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Hamburg : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hamburg : Site Reference ID/Investigator# 38169

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Hamburg : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hamburg : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Hannover :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Hannover : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Hannover : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Hannover : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Heidelberg :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Herne :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Kiel : Site Reference ID/Investigator# 38170

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Leipzig : Site Reference ID/Investigator# 44042

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Lÿneburg :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Minden : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Minden : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Minden : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Minden : GSK Investigational Site Updated

Open-Label Extension Study of GSK1605786A

Muenster : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

München :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Münster :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Tübingen :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Ulm : GSK Investigational Site Updated

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

Ulm : GSK Investigational Site Updated

GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease

Békéscsaba :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Debrecen :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Szekszard : Pfizer Investigational Site

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Ashkelon : Barzilai Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Haifa : Rambam Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Haifa : Bnai Zion Hospital

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Jerusalem :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Jerusalem : Shaarei Tzedek Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Jerusalem : Hadassah Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Kfar Saba : Meir Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Petah Tikva :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Rehovot : Kaplan Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Tel Aviv :

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

Tel Aviv : Tel Aviv Sourasky Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Tel Hashomer : Sheba Medical Center

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Zerifin : Assaf Harofeh

Multicenter Clinical Efficacy and Safety Study of Delayed Release 6MP in Crohn's Disease

Rome : Site Reference ID/Investigator# 38178

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Rozzano : Site Reference ID/Investigator# 38177

Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease

Aichi : Site Ref # / Investigator 48683